- Conditions
- Retinal Vein Occlusion, Macula Edema
- Interventions
- TLC399 (ProDex)
- Drug
- Lead sponsor
- Taiwan Liposome Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced May 21, 2026, 11:59 PM EDT